Specific Polymorphism 4G/5G Gene for PAI-1 as a Possible Cause of Cerebral Venous Thrombosis: A Case Report

1. Einhäupl K, Bousser MG, de Bruijn SF et al. (2006). EFNS guideline on the treatment of cerebral venous and sinus thrombosis. Eur J Neurol. 13 (6), 553–9.10.1111/j.1468-1331.2006.01398.x16796579Search in Google Scholar

2. deVeber G, Andrew M, Adams C et al. (2001). Cerebral sinovenous thrombosis in children. N Engl J Med. 345 (6), 417–23.10.1056/NEJM20010809345060411496852Search in Google Scholar

3. Wysokinska EM, Wysokinski WE, Brown RD et al. (2008). Thrombophilia differences in cerebral venous sinus and lower extremity deep venous thrombosis. Neurology. 19;70(8), 627-33.10.1212/01.wnl.0000297195.97325.a818285537Search in Google Scholar

4. Saadatnia M, Salehi M, Movahedian A et al (2015). Factor V Leiden, factor V Cambridge, factor II GA20210, and methylenetetrahydrofolate reductase in cerebral venous and sinus thrombosis: A case-control study. J Res Med Sci. 20 (6), 554–562.10.4103/1735-1995.165956462164926600830Search in Google Scholar

5. Countinho JM, Ferro JM, Canhão P et al. (2009). Cerebral Venous and Sinus Thrombosis in Women. Stroke. 40(7), 2356-2361.10.1161/STROKEAHA.108.54388419478226Search in Google Scholar

6. Flores-Barragan JM, Hernandez-Gonzalez A, Gallardo-Alcaniz MJ et al. (2009). Clinical and therapeutic heterogeneity of cerebral venous thrombosis: a description of a series of 20 cases. Rev Neurol. 49(11), 573-6.Search in Google Scholar

7. Purvin VA, Trobe JD, Kosmorsky G. (1995). Neuroophthalmic features of cerebral venous obstruction. Arch Neurol. 52(9), 880–885.10.1001/archneur.1995.005403300580157661725Search in Google Scholar

8. Ferro JM, Canhão P, Bousser MG et al. (2008). Early seizures in cerebral vein and dural sinus thrombosis: risk factors and role of antiepileptics. Stroke. 39(4), 1152–1158.10.1161/STROKEAHA.107.48736318309177Search in Google Scholar

9. Alvis-Miranda HR, Milena Castellar-Leones S, Alcala-Cerra G et al. (2013). Cerebral sinus venous thrombosis. J Neurosci Rural Pract. 4(4), 427-438.10.4103/0976-3147.120236385876224347950Search in Google Scholar

10. Mehta R, Shapiro AD. (2008). Plasminogen activator inhibitor type 1 deficiency. Haemophilia. 14(6), 1255-60.10.1111/j.1365-2516.2008.01834.x19141166Search in Google Scholar

11. Lee C.C, Tze-Sing H. (2005). Plasminogen Activator Inhibitor-1: The Expression, Biological Functions, and Effects on Tumorigenesis and Tumor Cell Adhesion and Migration. J Cancer Mol. 1(1), 25-36.Search in Google Scholar

12. Yasar Yildiz S, Kuru P, ToksoyOner E et al. (2014). Functional stability of plasminogen activator inhibitor-1. Scientific World Journal. 2014:858293.Search in Google Scholar

13. Đorđević V, Gvozdenov M, Pruner I et al. (2013). Učestalost PAI-1 4G/5Ggenske varijante u srpskoj populaciji. Medicinski glasnik Specijalna bolnica za bolesti štitaste žlezde I bolesti metabolizma Zlatibor. 18 (49), 28-41.Search in Google Scholar

14. Zhang H, Dong P, Yang X et al. (2014). Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with coronary artery disease risk: a meta-analysis. Int J ClinExp Med. 7(10), 3777-3788.Search in Google Scholar

15. Parpugga TK, Tatarunas V, Skipskis V et al (2015). The Effect of PAI-1 4G/5G Polymorphism and Clinical Factors on Coronary Artery Occlusion in Myocardial Infarction. Dis Markers. 2015:260101.Search in Google Scholar

16. Wang J, Wang C, Chen N et al. (2014). Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and risk of venous thromboembolism: a meta-analysis. Thromb Res. 134(6), 1241-8.10.1016/j.thromres.2014.09.03525450536Search in Google Scholar

17. Gohil R, Peck G, Sharma P. (2009). The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls. Thromb Haemost. 102(2), 360-70.10.1160/TH09-01-001319652888Search in Google Scholar

18. Doggen CJ, Bertina RM, Cats VM et al. (1999). The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction. Thromb Haemost. 82(1), 115-20.10.1055/s-0037-1614639Search in Google Scholar

19. Chen YL, Zhang JX, Wang PX et al. (2005). Association of 4G/5G polymorphism in PAI1 promoter with PAI1 level in deep vein thrombosis. Zhonghua Yi Xue Yi ChuanXue Za Zhi. 22(6), 624-7.Search in Google Scholar

20. Tsantes AE, Nikolopoulos GK, Bagos PG et al. (2007). Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of ischemic stroke: a meta-analysis. Blood Coagul Fibrinolysis. 18(5), 497-504.10.1097/MBC.0b013e3281ec4eee17581326Search in Google Scholar

21. Bentley P, Peck G, Smeeth L et al. (2010). Causal Relationship of Susceptibility Genes to Ischemic Stroke: Comparison to Ischemic Heart Disease and Biochemical Determinants. PLoS ONE. 5(2), e9136.10.1371/journal.pone.0009136281772620161734Search in Google Scholar

22. Ringelstein M, Jung A, Berger K et al. (2012). Promotor polymorphisms of plasminogen activator inhibitor-1 and other thrombophilic genotypes in cerebral venous thrombosis: a case-control study in adults. J Neurol. 259(11), 2287-92.10.1007/s00415-012-6477-722527222Search in Google Scholar

23. Xu F, Liu H, Sun Y. (2016). Association of plasminogen activator inhibitor-1 gene polymorphism and type 2 diabetic nephropathy. Ren Fail. 38(1), 157-62.10.3109/0886022X.2015.108946426616527Search in Google Scholar

24. Xu K, Liu X, Yang F et al. (2013). PAI-1-675 4G/5G polymorphism in association with diabetes and diabetic complications susceptibility: a meta-analysis study. PLoS One. 8(11), e79150.10.1371/journal.pone.0079150381846324223897Search in Google Scholar

25. Li X, Liu Y, Zhang R et al. (2015). Meta-analysis of the association between plasminogen activator inhibitor-1 4G/5G polymorphism and recurrent pregnancy loss. Med SciMonit. 21, 1051-6.10.12659/MSM.892898440349925862335Search in Google Scholar

26. Morgan JA, Bombell S, McGuire W. (2013). Association of plasminogen activator inhibitor-type 1 (-675 4G/5G) polymorphism with pre-eclampsia: systematic review. PLoS One. 8(2), e56907.10.1371/journal.pone.0056907357401823457639Search in Google Scholar

27. Lee YH, Song GG. (2014). Plasminogen activator inhibitor-1 4G/5G and the MTHFR 677C/T polymorphisms and susceptibility to polycystic ovary syndrome: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 175:8-14.Search in Google Scholar

28. Nie W, Li B, Xiu QY. (2012). The -675 4G/5G polymorphism in plasminogen activator inhibitor-1 gene is associated with risk of asthma: a meta-analysis. PLoS One. 7(3), e34385.10.1371/journal.pone.0034385331397822479620Search in Google Scholar

29. Li L, Nie W, Zhou H et al. (2013). Association between plasminogen activator inhibitor-1-675 4G/5G polymorphism and sepsis: a meta-analysis. PLoS One. 8(1), e54883.10.1371/journal.pone.0054883355984323382992Search in Google Scholar

30. Reshetniak TM, Ostriakova EV, Patrusheva NL et al. (2013). Plasminogen activator inhibitor type 1 gene polymorphism and thromboses in patients with antiphospholipid syndrome. TerArkh. 85(1), 76-84.Search in Google Scholar